Skip to content
10-Q

Quarterly Report

Lantern Pharma Inc. LTRN

0001493152-26-023740

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 11.3M sh
Shares Diluted Q1 2026 · Mar 31, 2026 11.25M sh
Shares Diluted Q1 2026 · Mar 31, 2025 10.78M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.77M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.38M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $4.92M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.42M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.45M
Stockholders Equity Q1 2026 · Dec 31, 2025 $6.53M
Stockholders Equity Q1 2026 · Mar 31, 2025 $16.78M
Stockholders Equity Q1 2026 · Dec 31, 2024 $21.19M
Current Liabilities Q1 2026 · Mar 31, 2026 $3.78M
Current Liabilities Q1 2026 · Dec 31, 2025 $4.5M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.78M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.5M
Current Assets Q1 2026 · Mar 31, 2026 $7.06M
Current Assets Q1 2026 · Dec 31, 2025 $10.8M
Total Assets Q1 2026 · Mar 31, 2026 $7.22M
Total Assets Q1 2026 · Dec 31, 2025 $11.04M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.30
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.42
Eps Basic Q1 2026 · Mar 31, 2026 −$0.30
Eps Basic Q1 2026 · Mar 31, 2025 −$0.42
Sga Expense Q1 2026 · Mar 31, 2026 $1.68M
Sga Expense Q1 2026 · Mar 31, 2025 $1.51M
Rd Expense Q1 2026 · Mar 31, 2026 $1.72M
Rd Expense Q1 2026 · Mar 31, 2025 $3.26M
Net Income Q1 2026 · Mar 31, 2026 −$3.33M
Net Income Q1 2026 · Mar 31, 2025 −$4.54M
Operating Income Q1 2026 · Mar 31, 2026 −$3.41M
Operating Income Q1 2026 · Mar 31, 2025 −$4.77M
Capex Q1 2026 · Mar 31, 2025 $1.16K